Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Lessons learned from the implementation of non-invasive fetal RHD screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Lan Xu
  • Ina Benoy
  • Kate Cuschieri
  • Mario Poljak
  • Jesper Bonde
  • Marc Arbyn
Vis graf over relationer

BACKGROUND: Genotyping for the most carcinogenic human papillomavirus (HPV) types (HPV16/HPV18) can identify high risk of underlying cervical precancer and guide further management.

RESEARCH DESIGN AND METHODS: A pooled analysis was performed of the clinical accuracy of high-risk HPV (hrHPV) testing and HPV16/18 genotyping in triage of women with low grade squamous intraepithelial lesions (LSIL). Data regarding 24 assays evaluated in four VALGENT validation panels were used.

RESULTS: In women with LSIL, hrHPV had a pooled sensitivity for CIN2+ of 95.5% (95% CI: 91.0-97.8%) and a specificity of 25.3% (95% CI: 22.2-28.6%). HPV16/18 genotyping had a sensitivity and specificity for CIN2+ of 52.9% (95% CI: 48.4-57.4%) and 83.5% (95% CI: 79.9-86.5%), respectively. The average risk of CIN2+ was 46.1% when HPV16/18-positive, 15.5% in women who were HPV16/18-negative but positive for other hrHPV types and 4.3% for hrHPV-negative women.

CONCLUSIONS: Triage of women with LSIL with HPV16/18 genotyping increases the positive predictive value compared to hrHPV testing but at the expense of lower sensitivity. Arguably, women testing positive for HPV16/18 need further clinical work-up. Whether colposcopy referral or further surveillance is recommended for women with other hrHPV types may depend on the post-test risk of precancer and the local risk-based decision thresholds.

OriginalsprogEngelsk
TidsskriftExpert Review of Molecular Diagnostics
Vol/bind19
Udgave nummer6
Sider (fra-til)543-551
Antal sider9
ISSN1473-7159
DOI
StatusUdgivet - jun. 2019

ID: 57074357